Image by pikisuperstar on Freepik On 18th October, Mablink Bioscience (“Mablink”) –Lyon, France– announced an agreement to be acquired by Eli Lilly and Company (“Lilly”). Mablink was created in December 2018, raised a total of EUR31m in equity and was readily...
The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. October 18, 2023 – Lyon, France Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company...
June 15, 2023 – Lyon, France Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing cancer therapy with next-generation antibody-drug conjugates (ADCs),today announced the appointment of Dr. Pejvack Motlagh, M.D., as Chief Medical...
January 20, 2023 – Lyon, France Mablink Bioscience (“Mablink”) announces the publication of a review article titled “Payload diversification: a key step in the development of antibody–drug conjugates”. Its authors Louise Conilh, Lenka Kyrych Sadilkova, Warren...
En 1874, Carl Vogt devint le premier Recteur de la nouvelle Université de Genève. En 2023, Eric Bauce, choisi par l’Assemblée de l’Université, en deviendra peut-être le nouveau Recteur. Il est frappant de voir le télescopage des controverses avec deux personnalités...
